Roivant Sciences Ltd. (NASDAQ:ROIV) Given Average Rating of "Moderate Buy" by Brokerages

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) has been given an average recommendation of "Moderate Buy" by the eight ratings firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $17.93.

Separately, HC Wainwright restated a "buy" rating and issued a $18.00 price objective on shares of Roivant Sciences in a research note on Wednesday, November 13th.

Insider Activity at Roivant Sciences

In other Roivant Sciences news, Director Sciences Ltd. Roivant acquired 16,845,010 shares of the company's stock in a transaction on Monday, January 13th. The shares were bought at an average cost of $20.00 per share, with a total value of $336,900,200.00. Following the completion of the acquisition, the director now owns 96,650,341 shares in the company, valued at approximately $1,933,006,820. This trade represents a 21.11 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Eric Venker sold 100,000 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $11.28, for a total value of $1,128,000.00. Following the transaction, the chief operating officer now owns 732,294 shares in the company, valued at $8,260,276.32. This trade represents a 12.01 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,942,629 shares of company stock worth $23,034,486. 7.90% of the stock is owned by company insiders.

Hedge Funds Weigh In On Roivant Sciences

Hedge funds have recently made changes to their positions in the company. Gladius Capital Management LP purchased a new position in Roivant Sciences in the 3rd quarter valued at $35,000. US Bancorp DE raised its position in shares of Roivant Sciences by 146.5% in the third quarter. US Bancorp DE now owns 3,278 shares of the company's stock valued at $38,000 after buying an additional 1,948 shares during the last quarter. GAMMA Investing LLC boosted its position in Roivant Sciences by 57.0% during the fourth quarter. GAMMA Investing LLC now owns 3,548 shares of the company's stock worth $42,000 after acquiring an additional 1,288 shares during the last quarter. Quarry LP purchased a new stake in Roivant Sciences during the 2nd quarter valued at about $53,000. Finally, Blue Trust Inc. raised its holdings in Roivant Sciences by 550.1% in the 4th quarter. Blue Trust Inc. now owns 7,879 shares of the company's stock valued at $91,000 after acquiring an additional 6,667 shares during the last quarter. Institutional investors and hedge funds own 64.76% of the company's stock.

Roivant Sciences Price Performance

NASDAQ:ROIV traded down $0.18 during trading hours on Tuesday, hitting $11.19. 1,959,327 shares of the company were exchanged, compared to its average volume of 4,063,823. Roivant Sciences has a 52-week low of $9.69 and a 52-week high of $13.06. The stock has a market capitalization of $8.15 billion, a price-to-earnings ratio of 1.98 and a beta of 1.27. The company's 50 day moving average price is $11.72 and its 200-day moving average price is $11.61.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.